Moreover, in 2022, the team of Rosen showed that inhibiting SUMOylation in myeloma cells resulted in decreased c-myc protein stability, which in turn decreased the levels of several miRNAs involved in either GR downregulation or GC resistance [62]. This evidence concerns the gene NR3C1 and plasma cell myeloma.